Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 15,875.0% in February

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 63,900 shares, an increase of 15,875.0% from the February 13th total of 400 shares. Based on an average daily trading volume, of 162,900 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Oncotelic Therapeutics Stock Down 1.9 %

OTLC opened at $0.05 on Friday. The company has a 50 day moving average of $0.04 and a 200 day moving average of $0.03. The company has a market cap of $21.53 million, a PE ratio of -5.30 and a beta of -0.25. Oncotelic Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.05. The company has a current ratio of 0.01, a quick ratio of 0.01 and a debt-to-equity ratio of 0.28.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.